Aspire Private Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aspire Private Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8	Closed	-$2.77K	–	696
2024 Q1	$2.77K	Hold	8	–	–	﹤0.01%	553
2023 Q4	$2.58K	Hold	8	–	–	﹤0.01%	540
2023 Q3	$2.87K	Hold	8	–	–	﹤0.01%	534
2023 Q2	$3.03K	Hold	8	–	–	﹤0.01%	504
2023 Q1	$3.83K	Sell	8 -1	-11%	-$468	﹤0.01%	474
2022 Q4	$3.78K	Hold	9	–	–	﹤0.01%	463
2022 Q3	$4K	Hold	9	–	–	﹤0.01%	432
2022 Q2	$4K	Hold	9	–	–	﹤0.01%	409
2022 Q1	$5K	Hold	9	–	–	﹤0.01%	392
2021 Q4	$7K	Sell	9 -1	-10%	-$748	﹤0.01%	366
2021 Q3	$7K	Hold	10	–	–	﹤0.01%	335
2021 Q2	$6K	Sell	10 -22	-69%	-$13.4K	﹤0.01%	361
2021 Q1	$18K	Buy	32 +30	+1,500%	+$17.8K	0.01%	279
2020 Q4	$1K	Hold	2	–	–	﹤0.01%	405
2020 Q3	$1K	Sell	2 -31	-94%	-$15.7K	﹤0.01%	408
2020 Q2	$15K	Buy	+33	New	+$14.6K	0.01%	198

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aspire Private Capital's BIO Position: Q2 2024 in Review

Aspire Private Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 8 shares — an estimated $2.77K sold.

Aspire Private Capital first reported a position in BIO in Q2 2020 and held it in 16 quarters. The position peaked at $18K in Q1 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Aspire Private Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Aspire Private Capital sold 8 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $2.77K.
Aspire Private Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 16 quarters.
Aspire Private Capital's Bio-Rad Laboratories Class A position peaked at $18K in Q1 2021.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Aspire Private Capital's 13F filing for Q2 2024, filed 15 Jul 2024.